| |
 |
MT110 is a recombinant bispecific single-chain antibody that was generated using Micromet's proprietary BiTE® antibody technology. MT110 consists of four immunoglobulin variable domains assembled into a single polypeptide chain. Two of the variable domains form the binding site for EpCAM, a cell surface antigen expressed on most solid tumors. The other two variable domains form the binding site for the CD3 complex on T cells. The resulting recombinant molecule is produced by fermentation with eukaryotic cells. BiTE antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy.
|
|
|
|
Status |
|
|
|
|  |  | Ongoing phase 1 clinical trial in patients with lung or gastrointestinal cancer |
|
|
|
|
|
|
|
|
BiTE® Antibody
MT110
|
|
